Skip to main content

PolyOrg Licenses Rights to PNA Monomers from Copenhagen Inventor Group

NEW YORK (GenomeWeb News) — PolyOrg said today that it has licensed from the Copenhagen Inventor Group the right to make and sell PNA monomers worldwide.

PNAs are oligonucleotide analogs in which the sugar-phosphate backbone of DNA is substituted by amino-ethyl-glycine backbone. They hybridize strongly to complementary DNA or RNA but are not degraded by nucleases or proteases, the company said, and they are useful for molecular biology and diagnostics applications and antisense and anti-gene therapies.

Under the non-exclusive license, PolyOrg will initially offer Fmoc/Bhoc protected monomers, which are are compatible with "several" commercially automated DNA/Peptide/PNA synthesizers, the company said.

Financial terms of the agreement were not released.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.